Transaction details
Director Rafael Flores executed a sale of 1,600 shares of Ameren Corp common stock on February 17, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at $111.52 each, producing a total transaction value of $178,432.
This sale took place while the stock was trading near its 52-week high of $112.66; the share price was reported at $109.80 at the time of the filing. Following the sale, Flores holds 13,953 shares directly in the company.
Company metrics and third-party analysis
Ameren is valued at approximately $30.35 billion on the market and trades at a price-to-earnings ratio of 20.24. The company pays a dividend yield of 2.73%. According to InvestingPro analysis, the stock appears slightly overvalued relative to its Fair Value. The company is included among more than 1,400 U.S. equities covered by InvestingPro's Pro Research Reports.
Quarterly results and market reaction
Ameren reported fourth-quarter results for 2025 that included an adjusted earnings per share of $0.78, narrowly surpassing the $0.77 consensus estimate. Revenue for the quarter was $1.78 billion, below the expected $1.83 billion. The report notes that the positive earnings surprise received a favorable investor response, while the revenue shortfall points to areas the company may need to address going forward.
Investors and analysts are monitoring these results to inform future performance assessments. The companys earnings beat has been characterized as an indicator of operational efficiency, whereas the revenue miss has been identified as a potential focus area for improvement. Analyst reactions to the quarter could affect subsequent evaluations of the stock.
Summary of the filing and context
- Rafael Flores sold 1,600 Ameren shares on Feb. 17, 2026, at $111.52 each for $178,432 in proceeds.
- After the sale Flores holds 13,953 Ameren shares.
- Amerens market cap is $30.35 billion, P/E is 20.24, and dividend yield is 2.73%.
- InvestingPro flags the stock as slightly overvalued against its Fair Value and lists the company within its Pro Research coverage universe of over 1,400 U.S. equities.
- Q4 2025 adjusted EPS was $0.78 versus an expected $0.77; Q4 revenue was $1.78 billion versus an expected $1.83 billion.
Notes
The information above is drawn from the reported Form 4 filing and the company's published quarterly figures. Market metrics and the InvestingPro valuation comment are presented as reported.